On May 2, 2025, Citigroup analyst Patrick Donnelly maintained a "Buy" rating for Bio-Rad Laboratories (BIO, Financial). Despite the consistent rating, the analyst has adjusted the price target for the stock. The price target has been lowered from the previous $400.00 to a current valuation of $350.00.
This adjustment marks a 12.5% decrease in the price target while maintaining a positive outlook on the stock by continuing the "Buy" recommendation. The adjustments by Citigroup analysts suggest a recalibration of expectations for Bio-Rad Laboratories (BIO, Financial), taking into account market trends and company performance forecasts.
Investors should note that while the price target has been reduced, the maintained "Buy" rating reflects Citigroup's confidence in the company's fundamental strengths and potential for future growth. The stock continues to be listed on NYSE.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 6 analysts, the average target price for Bio-Rad Laboratories Inc (BIO, Financial) is $349.83 with a high estimate of $409.00 and a low estimate of $270.00. The average target implies an upside of 48.02% from the current price of $236.34. More detailed estimate data can be found on the Bio-Rad Laboratories Inc (BIO) Forecast page.
Based on the consensus recommendation from 7 brokerage firms, Bio-Rad Laboratories Inc's (BIO, Financial) average brokerage recommendation is currently 2.3, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Bio-Rad Laboratories Inc (BIO, Financial) in one year is $370.82, suggesting a upside of 56.9% from the current price of $236.34. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Bio-Rad Laboratories Inc (BIO) Summary page.
